Michal Nath Puri - 02 Nov 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 16:05:52 UTC
Prior SEC filing
01 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Steven Robbins, as attorney in fact for Puri, Michal Nath
Filing notes and source

Key filing fact

Michal Nath Puri filed Form 4 for NovoCure Ltd (NVCR) on 04 Nov 2026.

Key facts

  • This page summarizes Michal Nath Puri's Form 4 filing for NovoCure Ltd (NVCR).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 04 Nov 2026, 16:05.

Change

  • Previous filing in this sequence was filed on 01 Jul 2026.
  • Current net transaction value: -$8,738.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997032 Primary reporting owner

Puri Michal Nath

Relationship
Chief Human Resources Officer
Address
C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature
Steven Robbins, as attorney in fact for Puri, Michal Nath
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Sale

Transaction value
-$8,738
Shares
-660
Change %
-0.32%
Price
$13.24
Shares after
202,567
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $13.08 USD to $13.36 USD; the price reported above reflects the weighted average sale price.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .